Metraipolis › archive › dc_cfdd9a8dee03

Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity — Europe PMC PMID:42255825

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42255825
DOI
10.7759/cureus.108385
License (as archived)
solo-consultazione
Archived
2026-11-02T17:52:15.507Z
SHA-256 of the archived text
ad975d29e14616ab441eb798a7a6eaca95157a3beb2a443d5073a00f31ce4f32
Stable URL of this page
https://metraipolis.com/documento/dc_cfdd9a8dee03

How to cite

Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity — Europe PMC PMID:42255825 — Europe PMC (en), https://europepmc.org/article/MED/42255825 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cfdd9a8dee03 (Metraipolis archive dc_cfdd9a8dee03, sha256 ad975d29e14616ab441eb798a7a6eaca95157a3beb2a443d5073a00f31ce4f32)
BibTeX
@misc{dccfdd9a8dee03,
  title = {Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity — Europe PMC PMID:42255825},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42255825},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cfdd9a8dee03; sha256 ad975d29e14616ab441eb798a7a6eaca95157a3beb2a443d5073a00f31ce4f32},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42255825. Agents can read the archived copy with the MCP tool read_document.